Valuation: NFL Biosciences

Market Cap 11.02M 12.68M 10.26M 9.42M 17.79M 1.21B 18.07M 121M 47.47M 603M 47.63M 46.58M 2.02B P/E 2024
-9.56x
P/E 2025 -4.62x
Enterprise Value 9.41M 10.82M 8.75M 8.04M 15.18M 1.03B 15.41M 103M 40.5M 514M 40.63M 39.74M 1.72B EV / Sales 2024
370,592x
EV / Sales 2025 70,790x
Free-Float
85.79%
Yield 2024 *
-
Yield 2025 -
1 day+2.72%
1 week+4.82%
1 month+0.58%
3 months-14.71%
6 months-32.14%
Current year-26.15%
1 week 0.82
Extreme 0.82
0.87
1 month 0.82
Extreme 0.82
0.9
Current year 0.8
Extreme 0.8
1.85
1 year 0.8
Extreme 0.8
1.85
3 years 0.8
Extreme 0.8
3.31
5 years 0.55
Extreme 0.548
5
10 years 0.55
Extreme 0.548
5
Manager TitleAgeSince
Chief Executive Officer - 2024-10-16
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman - 2023-02-26
Chairman - 2024-10-16
Director/Board Member - 2021-05-18
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+4.82%-32.14%-64.78% 12.68M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average +0.16%-2.93%+29.07%+132.85% 23.39B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.83%

Financials

2024 2025
Net sales 46 52.92 42.82 39.31 74.23 5.05K 75.38 504.69 198.08 2.51K 198.73 194.37 8.43K 188 216.27 174.99 160.66 303.39 20.64K 308.09 2.06K 809.53 10.28K 812.21 794.37 34.46K
Net income -2.08M -2.39M -1.94M -1.78M -3.36M -229M -3.41M -22.83M -8.96M -114M -8.99M -8.79M -381M -3.32M -3.82M -3.09M -2.84M -5.35M -364M -5.44M -36.4M -14.29M -181M -14.33M -14.02M -608M
Net Debt -2.07M -2.38M -1.93M -1.77M -3.34M -228M -3.4M -22.74M -8.92M -113M -8.95M -8.76M -380M -1.62M -1.86M -1.51M -1.38M -2.61M -178M -2.65M -17.77M -6.97M -88.53M -7M -6.84M -297M
Logo NFL Biosciences
NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).
Employees
4
Date Price Change Volume
26-07-31 €0.8700 +2.72% 32,274
26-07-30 €0.8470 +2.17% 8,429
26-07-29 €0.8290 +1.10% 21,520
26-07-28 €0.8200 -2.26% 8,657
26-07-27 €0.8390 +1.08% 11,865

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNFL Stock